Phillips K A
Body Dysmorphic Disorder Program, Butler Hospital, Providence, RI 02906, USA.
Psychopharmacol Bull. 1996;32(4):597-605.
Body dysmorphic disorder (BDD), a preoccupation with an imagined or slight defect in appearance, has been described for more than a century and reported around the world. However, investigation into the treatment of this distressing and impairing disorder is just beginning. Available data on the pharmacologic treatment of BDD suggest that it often responds to serotonin reuptake inhibitors (SRIs), which may be preferentially effective for this disorder. Augmentation of SRIs with buspirone and neuroleptics, as well as combinations of SRIs, also appear promising. Available data also suggest that serotonin reuptake inhibitors may be effective for delusional BDD (a type of delusional disorder, somatic type). Because controlled treatment studies are lacking, however, these findings are preliminary. Controlled pharmacotherapy studies, which are under way, are greatly needed.
躯体变形障碍（BDD），即过度关注想象中的或轻微的外表缺陷，这一病症已被描述了一个多世纪，且在世界各地均有报道。然而，针对这种令人痛苦且有损身心健康的疾病的治疗研究才刚刚起步。关于BDD药物治疗的现有数据表明，它通常对5-羟色胺再摄取抑制剂（SRIs）有反应，这类药物可能对该疾病具有优先疗效。用丁螺环酮和抗精神病药物增强SRIs的疗效，以及SRIs的联合使用，似乎也很有前景。现有数据还表明，5-羟色胺再摄取抑制剂可能对妄想型BDD（一种妄想障碍，躯体类型）有效。然而，由于缺乏对照治疗研究，这些发现只是初步的。目前正在进行的对照药物治疗研究非常必要。
